-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The famous American movie star Angelina Jolie wrote an article "My Medical Choices" in May 2013, claiming that through genetic testing, she was determined to carry the BRCA1 mutation.
BRCA gene is the top priority of genetic testing for hereditary ovarian cancer
BRCA gene is the top priority of genetic testing for hereditary ovarian cancerPersonal genetic factors play an important role in the occurrence and development of tumors, and determine the susceptibility of individuals to tumors
In all ovarian cancer patients, HBOCS accounts for 10%-15%.
BRCA mutation is the gold standard for opening first-line maintenance treatment of ovarian cancer with PARP inhibitors
BRCA mutation is the gold standard for opening first-line maintenance treatment of ovarian cancer with PARP inhibitorsA study of patients with hereditary ovarian cancer found that patients with BRCA1/2 gene pathogenic mutations usually have a better prognosis.
Based on the outstanding results of the PARP inhibitor olaparib SOLO-1, the FDA quickly approved it as a long-term maintenance treatment for patients with BRCA-mutated ovarian cancer, fallopian tube cancer, and primary peritoneal cancer after first-line chemotherapy after reaching PR or CR after first-line chemotherapy
Figure 1.
It should be noted that although the follow-up time of the SOLO1 study is 5 years, the median treatment time of the olaparib group is only 24.
Figure 2.
The BRCA1/2 gene is the most important biomarker to assess the risk of ovarian cancer and influence the choice of individualized treatment options for patients.
HRD testing expands groups benefiting from maintenance therapy with PARP inhibitors for ovarian cancer
HRD testing expands groups benefiting from maintenance therapy with PARP inhibitors for ovarian cancerAs mentioned earlier, in addition to the BRCA1/2 gene, there are many genes that are closely related to the occurrence and development of ovarian cancer
In summary, genetic testing of patients with ovarian cancer and screening for pathogenic mutations can help doctors perform precise treatments on patients.
【references】
[1[Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
[2]2020 ESMO Abs 811MO
[3]2020 "NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian"